Loading...
Loading...
Dr. Reddy's Laboratories
RDY,
announced today the U.S. Food and Drug Administration (US FDA) tentative
approval for Zenavod™ (doxycycline) Capsules, 40 mg. Zenavod is a
tetracycline-class drug indicated for the treatment of only inflammatory
lesions (papules and pustules) of rosacea in adult patients. Promius™
Pharma, LLC, the U.S. subsidiary of India's Dr. Reddy's Laboratories
will be responsible for commercializing Zenavod in the U.S. market.
"This development confirms our ability and commitment to develop
differentiated dermatology products leveraging the in-house capabilities
of Promius Pharma, LLC and Dr. Reddy's," stated G V Prasad, CEO and
Co-Chairman, Dr. Reddy's Laboratories. He continued, "We are pleased to
receive a tentative FDA
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in